Navigation Links
Neurocrine Biosciences Reports Fourth Quarter and Year-End 2008 Results
Date:2/3/2009

al work for urocortin 2 was successfully completed, and we advanced another compound, a VMAT2 inhibitor, now ready for clinical development. We pushed all these initiatives forward while meeting our main financial goal to end 2008 with over $100 million in cash and investments," said Kevin C. Gorman, President and CEO of Neurocrine Biosciences.

2009 Financial Guidance

Exclusive of any new partnering agreements, the Company expects to have a cash burn in 2009 of approximately $50 to $55 million. This projected burn includes all the activities necessary for completion of the Phase II program for elagolix and requesting the end of Phase II meeting with the FDA in the fourth quarter of 2009.

Pipeline Highlights

The Company's clinical development group and corporate partners are advancing its lead programs through development. Neurocrine scientists continue to build the Company's pipeline to meet the Company-wide goal of bringing one new compound into development each year.

GnRH Antagonists in Expanded Phase II Clinical Trials for Endometriosis

Elagolix for Endometriosis

During 2008, the Company announced the positive safety and efficacy results from the completed 6-month treatment phase of its Phase IIb clinical trial (PETAL Study) using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix.

The primary endpoint, percent change from baseline in mean bone mineral density (BMD) demonstrated elagolix did not induce significant bone loss over the six month treatment period. Additionally, elagolix also met the secondary endpoints of improvement in endometriosis symptoms using several different scales for endometriosis pain. The 6-month results from this study, together with data from the other Phase II studies, will be the basis for secur
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Webcast Alert: Neurocrine Announces 1Q08 Financial Results
2. Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets
3. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
4. Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies
5. New Jersey-Based Biotech Start-Up Nexomics Biosciences Gets Off the Ground
6. URMC, Lighthouse Biosciences Awarded U.S. Patent for Diagnostic Technology
7. URMC, Lighthouse Biosciences awarded US patent for diagnostic technology
8. Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
9. CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform
10. Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus
11. Alexander R. Giaquinto, Ph.D., Joins Regado Biosciences as Senior Vice President of Regulatory Affairs and Quality Assurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Raises Significant Funds to Benefit of Children with Autism ... Taylor, Gary Cole and Zachary Levi Join Ben Stiller ... ANGELES, Dec. 16 At its 13th annual ... individuals. Hasbro President & CEO Brian ... in recognition of his far-reaching philanthropic leadership and commitment ...
(Date:12/16/2009)... -- Every year in the United States, 160,000 cases ... of the disease, making it the second leading cause ... , As researchers and clinicians fervently look for causes ... of studies producing more and more promising results ... genetics at Case Western Reserve University School of Medicine ...
(Date:12/16/2009)... Immucor, Inc. (Nasdaq: BLUD ), a global leader ... industry, today announced that Paul D. Mintz, M.D. has ... director, effective January 1, 2010. ,, Dr. Mintz ... for more than 30 years. He is a tenured ... Virginia School of Medicine. He also serves as director ...
(Date:12/16/2009)... Allscripts (Nasdaq: MDRX ) announced today that ... three and six months ended November 30, 2009 ... 11, 2010. Allscripts management will host a conference ... and other information at 8:30 AM Eastern Standard ... http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO ) ,, Allscripts fiscal second quarter earnings ...
(Date:12/16/2009)... widely used human embryonic stem cell lines lack genetic ... must be addressed to ensure that all sectors of ... University of Michigan research team. ,, In the first ... 47 embryonic stem cell lines, including most of the ... determined the genetic ancestry of each line and found ...
Breaking Medicine News(10 mins):Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 2Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 3Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 4Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 5Health News:New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer' 2Health News:New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer' 3Health News:Immucor Appoints New Board Director 2Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 2Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 3Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 4Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 2Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 3Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 4Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 5
... tumor disease has affected the ecological balance existing between native ... disease the number of devils has sharply reduced. David Pemberton ... the devil population in the Mt William National Park. ... see carcasses lying around the area. Wedge-tailed eagles are feeding ...
... research done by Dr Allan Pantuck it was found that ... , Prostate cancer is the most common cancer affecting men ... each year and about 10,000 die from the disease. ... presence of prostate cancer. But study shows that consumption of ...
... has revealed that having several older brothers increases the chances ... adds //weight to the idea of a biological basis for ... University in St Catharines, Canada said, "It's likely to be ... is probably a biological basis for homosexuality." ,S ...
... be associated with reduced length of antibiotic treatment for ... ,A biomarker of infection, procalcitonin appeared to ... therapy as compared with other parameters. ,The ... kind, appears in the first issue for July 2006 ...
... August, and Uganda will have one more problem to surmount ... stock of free antiretroviral//. Soon, Uganda will be left with ... grips of disease. ,The stock is said to ... ups will not have enough to tide over the next ...
... from Laval University, Quebec say that chronic job stress ... white-collar workers. // ,The research, appearing in the ... levels and tight deadlines increased blood pressure especially in ... seven years. "Our study supports the hypothesis that job ...
Other Medicine News:Health News:Procalcitonin-Guided Antibiotic Therapy Proved Effective in CAP Cure 2Health News:Procalcitonin-Guided Antibiotic Therapy Proved Effective in CAP Cure 3
(Date:12/16/2009)... Dec. 16 According to Millennium Research ... market intelligence, health care reforms in China supported ... in 2009, and will continue to fuel growth ... Asia Pacific Markets for Interventional Cardiology Devices 2010 ... Chinese government will allow the Chinese drug-eluting stent ...
(Date:12/16/2009)... -- Biovista Inc.,today announced that it was awarded ... the 2009 New England Venture Summit, held on ... cutting edge private companies,driving the future of innovation, ... other privately held companies that play a leading ... Clean-tech sectors. , "We ...
(Date:12/16/2009)... -- BioSpecifics Technologies Corp. (Nasdaq: BSTC ), ... products, today announced top-line efficacy and safety results ... for the treatment of Peyronie,s disease. Peyronie,s disease ... on the shaft of the penis, which can ... or impossible in advanced cases. The Phase 2b ...
Breaking Medicine Technology:Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group 2Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group 3Biovista Inc. Named Top Innovator in Life Sciences 2BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 2BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 3BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 4No Link Found Between Birth Anesthesia and Learning Issues 53665 1No Link Found Between Birth Anesthesia and Learning Issues 53665 2Certain Arthritis Crohns Drugs May Raise Kids Cancer Risk 3A FDA 53660 1Certain Arthritis Crohns Drugs May Raise Kids Cancer Risk 3A FDA 53660 2Certain Arthritis Crohns Drugs May Raise Kids Cancer Risk 3A FDA 53660 3Silenced genes as a warning sign of blood cancer 53655 1Silenced genes as a warning sign of blood cancer 53655 2
... study evaluating DUROS(R) continuous delivery of exenatide for the ... Intarcia Therapeutics, Inc. today announced the completion of patient ... 650 (DUROS(R) continuous delivery of exenatide). The study is ... and involves the treatment of 44 patients with type ...
... Trial Expected to Initiate in 2010 for BlinatumomabNEW YORK, ... ), a biopharmaceutical company developing novel, proprietary antibodies for ... held an R&D Day for investors and financial analysts ... The presentations highlighted significant areas of development across Micromet,s ...
Other Medicine Technology:Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes 2Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes 3Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 2Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 3Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 4
Corning 7078 Calibrated"to deliver". multi-pack plugged capacity 5 mL...
... operative hysteroscopy, the surgeon and O.R. staff ... the dangers of fluid intravasation. Manual methods ... solution is the DOLPHIN II Fluid Management ... market leader in endoscopic irrigation. It has ...
... precision 4mL PYREX volumetric pipets ... Contain" (TC - bottom line) ... top line) to specifications for ... are color-coded with colored graduations ...
1000L...
Medicine Products: